{
    "Trade/Device Name(s)": [
        "SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay"
    ],
    "Submitter Information": "Immunalysis Corporation",
    "510(k) Number": "K203564",
    "Predicate Device Reference 510(k) Number(s)": [
        "K101754"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "October 7, 2021",
    "Summary Letter Received Date": "October 8, 2021",
    "Submission Date": "October 7, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Oxycodone"
    ],
    "Specimen Type(s)": [
        "Oral fluid"
    ],
    "Specimen Container(s)": [
        "Quantisal Oral Fluid Collection Device",
        "Quantisal II Oral Fluid Collection Device"
    ],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzer",
        "Beckman Coulter AU480 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay, a homogeneous enzyme immunoassay for qualitative and semi-quantitative analysis of oxycodone in oral fluid",
    "Indications for Use Summary": "For in vitro diagnostic use; qualitative and semi-quantitative analysis of oxycodone in human oral fluid collected by Quantisal or Quantisal II Oral Fluid Collection Device using clinical analyzers",
    "fda_folder": "Toxicology"
}